A sensitive Interactome-based approach to characterize drug activity in living human cells.
Abnormal protein-protein interactions (PPIs) involving signaling proteins contribute to numerous human diseases. Targeting such aberrant PPIs with selective inhibitory molecules is a promising therapeutic strategy, yet assessing how many PPIs are affected by a candidate drug, and whether inhibition occurs before or aft...